

Investor Day 2021 Sustaining Profitable Growth

September 17, 2021

	Торіс	Speaker
8:30am	Welcome and Logistics	– Ron Kurtz
8:35am	Sustaining Profitable Growth	 Joe Zubretsky
9:30am	Compelling Financial Profile	 Mark Keim
10:00am – 10:45am	Executive Q&A	 Joe Zubretsky Mark Keim



Cautionary Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:


This presentation and the accompanying oral remarks include forward-looking statements regarding, without limitation, the Company's 2021 guidance, its 2022 premium revenue and revenue growth strategy, its long-term financial targets and margin outlook, the COVID pandemic, COVID risk sharing corridors, future RFPs and re-procurements, mergers and acquisitions, Medicaid redeterminations, and the Company's general business plans. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward looking statements contained in the Private Securities Litigation Reform Act of 1995. Readers and listeners are cautioned not to place undue reliance on any forwardlooking statements as forward-looking statements are not guarantees of future performance, and the Company's actual results may differ materially due to numerous known and unknown risks and uncertainties. Those risks and uncertainties are discussed under Item 1A in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, and also in the Company's quarterly reports, current reports, and other reports and filings with the Securities and Exchange Commission, or SEC. These reports can be accessed under the investor relations tab of the Company's website or on the SEC's website at www.sec.gov. All forward looking statements in this presentation represent management's judgment as of September 17, 2021, and, except as otherwise required by law, the Company disclaims any obligation to update any forward-looking statements to conform the statement to actual results or changes in its expectations.






Sustaining Profitable Growth

Joe Zubretsky President and Chief Executive Officer




Long-Term Financial Targets



Long-Term Premium Revenue Growth

Strong organic growth opportunities off of 2022 outlook, complemented by disciplined acquisition strategy



Long-Term Margin Outlook

Continued margin management will drive net income growth

Pre-Tax Margin Medical Care Ratio 4% - 5% Medicaid 88% - 89% <7% Medicare 87% - 88% 87% - 88% Marketplace 78% - 80% Weighted Total 87% - 88% Medical Care Ratio Adj. G&A Ratio Pre-Tax Margin

Total Company Long-Term Outlook


Strong revenue and earnings growth off of 2022 outlook, enhanced by operating leverage and share repurchases

Premium Revenue Growth	13% - 15%
Hedge to Margins / Operating Leverage	0% - 1%
Net Income Growth	13% - 16%
Share Repurchases	~2%
EPS Growth	15% - 18%



Investment Thesis

Strong growth, sustained margins and disciplined capital management form the core of shareholder return



Our Value Creating Franchise



Franchise

Leading pure-play, government-sponsored managed care company with breadth and scale



Mission

We improve the health and lives of our members by delivering high-quality health care

Molina provides access to high-quality government sponsored healthcare

Our mission is balanced among all those we serve





Members

*

Shareholders



Government Agencies




Employees



Transformation


Our transformation has driven strong growth in revenue, EPS and shareholder return




Portfolio

Geographically diversified government-services portfolio with strong segment synergies

Strong Incumbent in 18 States With No State Greater than 20% of Portfolio Revenue




Synergistic Medicare and Marketplace Segments Complement Medicaid





Portfolio Synergies


Synergistic product segments provide member continuity and leverage common capabilities





Market Share Upside Opportunity

National franchise with significant local market opportunity in all segments




Sources: Health Management Associates, State-reported data, CMS and Decision Resources Group



Attractive Government Managed Care Market

The Government Managed Care Market

Our addressable markets exceed \$1T in spend with high growth



Sources: CMS Medicaid Actuarial Report, NHE, KFF, HHS and Urban Institute



Political / Regulatory Environment

Political and regulatory environment provides favorable conditions for all segments

	Medicaid	Medicare	Marketplace
Executive Orders	Revoked Medicaid work requirements	PHE continues telehealth flexibility increasing access	Agencies halt sale of limited duration/non-ACA compliant plans
Legislation	ARP provides FMAP incentives for remaining states to expand Medicaid	Sequestration extends through 2021, boosting premiums	ACA premium subsidies increase for 2021 and 2022
Regulation	Rating rules tighten actuarial soundness requirements for quality withholds	CMS direct contracting opportunities	NBPP helps Medicaid enrollees transition easily to Marketplace after the PHE ends



Medicaid Rate Environment

Core rates are expected to remain actuarially sound with many COVID risk sharing corridors expiring

Core Rates	 Prospective rate setting in return to traditional methodology
	 Clear visibility on 2022 rates for 25% of premium revenue
	Rates reflect pre-COVID baseline trended forward and are actuarily sound
	 Rates reflect pre-COVID baseline trended forward and are actuarily sound


COVID Risk Sharing Corridors

- COVID risk sharing corridors in many states through 2021
- Corridors expected to end with PHE
- Corridors already expired in CA, NY, SC, and MI for 2022 fiscal years



Economic Recovery Trends

Medicaid enrollment increases with economic downturns, continually growing without returning to previous levels



Sources: CMS, BLS, MACPAC and KFF



The Profitable Growth Playbook

Medicaid / Medicare / Marketplace / M&A / Margin Profile

Medicaid


Medicaid Long-Term Organic Growth

Long-term organic growth rate of 8%-10% driven by current footprint and strategic initiatives



Increase Market Share

Retain existing contracts and focus on fundamental operating tactics to drive significant market share opportunity



Actions


- Engage membership redeterminations proactively
- Engage providers to drive membership
- Increase auto assignment through improved quality scores
- Drive voluntary enrollment through community presence and awareness



~**\$1.6B** 2025 Revenue Opportunity

Grow with Potential Expansion States


Opportunity in five incumbent states represents ~3 million additional Medicaid managed care lives





Pursue Carve-in Opportunities

Numerous pending LTSS and BH carve-in opportunities as states leverage managed care efficiency




Sources: CMS and Company estimates



New State RFP Pipeline

New state procurement opportunities total ~\$95 billion in annual premium revenue by 2025





2025 Premium Revenue

Prioritizing Opportunities

Significant RFP opportunities drive incremental long-term revenue growth

Key Criteria	Sizing the Opportunity	
1 Size and duration of contract	2025 total RFP opportunity	~\$95B
2 Strength of incumbents	Pursue subset of opportunities	~40%
3 Number of awardees	Projected competitive win rate	~50%
4 Access to high-quality low-cost network	Projected market share	~20%
5 Rational rate environment	2025 Molina revenue opportunity	~\$4B

Nevada RFP Win

Recently announced Nevada RFP award demonstrates continued success in new states



On August 17th, Molina announced award of new state Medicaid contract in Nevada

- Award covers beneficiaries through TANF,
 CHIP and Medicaid expansion programs
- Four-year contract term with potential twoyear extension
- Future opportunities in LTSS and ABD
- Strong ground game and innovative differentiation drove success

2022 Premium Revenue Expectation






Medicare


Medicare Long-Term Growth

Long-term organic growth rate of 11%-13% driven by current footprint and strategic initiatives



Increase D-SNP Market Shares in Current Medicare Service Areas

Fundamental operating tactics drive significant market share opportunity



Actions


- Expand direct sales channels
- Deepen targeted broker relationships
- Develop key provider relationships
- Improve retention through member engagement






Penetrate Medicaid Service Areas

D-SNP penetration of remaining Medicaid footprint provides significant opportunity






HEALTHCARE

Introduce Low-Income MA-PD Products

Low-income MA-PD products double Molina's market opportunity in Medicare



Actions Introduce low-income MAPD in current Medicaid footprint Target Marketplace and Medicaid age-ins Leverage existing direct sales and broker networks ~2% ~\$700M Service Area Share of 2025 Revenue Medicaid Footprint Opportunity


Sources: CMS and Company estimates



Marketplace

Strong 2021 Market Growth

Increased subsidies through ARP drove strong growth in 2021 with future growth rate expected to moderate




Market Dynamics

- More members are now eligible for zero-dollar silver plans
- Subsidy eligible population expanded through elimination of 400% FPL "cliff"
- Special enrollment period extended window for additional sign-ups
- Continuation of higher subsidies beyond 2022 currently under legislative review

Source: CMS, Urban Institute and HHS


Marketplace Long-Term Growth


As a smaller complement to Molina's core Medicaid franchise, Marketplace margin discipline will be prioritized over volume




Penetrate Medicaid Service Areas

Marketplace penetration of remaining Medicaid footprint provides significant revenue opportunity, balanced with margin discipline







HEALTHCARE

A&M

Our M&A Platform

M&A is a key element of our long-term premium growth outlook



Ample excess cash flow to deploy for acquisitions



Previously announced purchase prices are highly capital efficient

2

No need to access equity markets



Underperforming properties yield "sweat equity" accretion




M&A generally more accretive than new procurement economics



Expert integration teams

Acquisition History


Five transactions totaling ~\$8 billion of run-rate revenue sequenced for manageable integration



Margin Profile

Margin Management Performance

Strong MCR and G&A management programs continue to drive attractive margins



Medical Cost Management

Numerous capabilities to drive medical cost efficiencies, with focus on high acuity populations



Operating Focus

- Implemented state-of-the-art medical economics platform
- Centralized utilization management
- Enhanced high acuity care management
- Created Centers of Excellence for Behavioral, Rx and LTSS
- Focused on core technology, automation and quality

Optimal Operating Platform

Fully integrated blend of proprietary and best-of-breed partners provides winning combination

Internal	Hybrid	Outsourced
 Care management 	 Utilization management 	- Pharmacy
 Provider contracting 	 Transaction services 	 IT infrastructure
 Quality 	 Risk adjustment 	
 Community engagement 		
 Pricing and rating 		


Differentiated Capabilities



Winning Leadership Model

Proven Operating Model

While fairly traditional, our operating model and management process are executed with rigor and discipline




How We Operate


- Flat organizational structure
- Empowered local decision making
- Simplified matrix
- Appropriate delegated authority
- Manage by the numbers

Executive Team

Proven industry-leading team with over 20 decades of experience. Operating Council acts as a virtual COO



Value Creation Dynamics



Value Creation Dynamics


Highly efficient capital generation and deployment model creates significant value

Organic	Acquisitions	Enterprise
 Strong market growth trends Numerous strategic initiatives Capitalized at <10% of revenue Low volatility 	 Numerous pipeline opportunities Announced acquisitions at attractive valuations Turnaround opportunities drive strong EPS accretion 	 Cost structure yields significant operating leverage High conversion of net income to cash flow Attractive capital redeployment opportunities
8% - 10% revenue growth ~60% levered ROE	~5% revenue growth ~20% levered ROE	13% - 15% revenue growth 15% - 18% EPS growth



Investment Thesis

Strong growth, sustained margins and disciplined capital management form the core of shareholder return





Compelling Financial Profile

Mark Keim Chief Financial Officer

Compelling Financial Profile



Strong Capital Foundation

Strong balance sheet provides foundation for stability and growth

2Q21 Credit Stats		Reserve Strength			
Net Debt to EBITDA Ratio	1.7x	Reserves at 6/30/21	\$2.9B		
Net Debt / Capitalization	~43%		·		
Revolver Capacity	\$1B	Days in Claims Payable	48 Days		
Current Acquisition Capacity		Recurring Parent Cash Flow			
Parent Company Cash	~\$400M	Dividends to Parent	~\$700M		
Debt Capacity	~\$1B	Incremental Debt Capacity	>\$700M		

Capital Deployment Discipline


Capital deployed to highest return opportunities

Re-invest in Business	 Organic growth is the highest priority Most efficient use of capital to grow All lines of business are high growth 	
Accretive Acquisitions	 Robust pipeline Disciplined approach Strategic fit, operational synergies and EPS accretion 	
Return to Shareholders	 Convertible debt retired Share repurchases 	

EPS Accretion

Capital Deployment History

Demonstrated record of capital management enhances shareholder value






Announced acquisitions at attractive valuations drive strong EPS accretion

	Acquired	Purchas		
Target	Revenue (\$ M)	Announced Price (\$ M)	% of Revenue (Including Capital)	Run Rate EPS Impact
YourCare Health Plan	\$300	\$40	21%	\$0.20
Magellan Complete Care	\$2,900	\$820	28%	\$1.75
Passport Health Plan	\$2,000	\$66	11%	\$0.35
Affinity Health Plan	\$1,600	\$380	28%	\$0.60
Cigna's Texas Medicaid	\$1,000	\$60	15%	\$0.50
Total	\$7,800	\$1,366	22%	>\$3.00

Acquisition Pipeline

Acquisition pipeline remains robust with many remaining opportunities




G&A Expense Management

Continued expense management and positive operating leverage fund investments while reducing G&A ratio

÷

Expense Management

- Automation and process redesign
- Digitization
- Outsourcing
- Centralization to Center of Excellence
- Transparency and discipline



Building Capabilities

- Member and provider experience
- New business development
- M&A integration
- Medical economics and data analytics
- Population health


Full-Year 2021 Guidance

Reiterating adjusted EPS of no less than \$13.25 on higher revenue and underlying earnings power offset by higher expected net effect of COVID

Guidance		Embedded Earnings Power				
Total Revenue	>\$27 B	Net Effect of COVID	~\$3.00			
Premium Revenue >\$26 B		Medicare Risk Scores	\$1.00			
Adjusted EPS	no less than \$13.25	Acquisitions at Portfolio Margin	\$2.00			
		Total	~\$6.00			

Initial 2022 Premium Revenue Outlook

2022 premium revenue growth outlook of 12% before Marketplace enrollment changes and additional strategic initiatives / acquisitions





Medicaid Redetermination


Several factors are expected to drive a soft landing and 2022 revenue impact of ~\$0.5B and another ~\$0.8B in 2023

Timing	Duration	Eligibility				
CMS suggests PHE "likely" extended through 2021 year-end. Several states have already set their own timeline	With practical limitations of redetermining 80M members, CMS has now extended to maximum of one yearPrecedent and COVID outloo retention of many members through lapse in redetermining					
750,000 Members gained organically since beginning of pandemic	One year	375,000 Estimated 50% of members retained				
FY 2021		FY 2022 FY 2023				
~8.2M	FY Member Months	~6.7M ~4.5M				
~\$2.9B	Implied Revenue	~\$2.4B ~\$1.6B				



Long-Term Premium Revenue Growth

Balanced growth driven by significant organic growth opportunities and disciplined acquisition strategy





Long-Term Organic Premium Revenue Growth Model

Targeted organic growth rates driven by identified strategic initiatives

	Current	S				
	Footprint Eligibles + Yield	2025 Revenue Opportunity	Discounted Outcome	3-Year Implied CAGR off of 2022	Long-Term Organic Growth Rate	
Medicaid	4%	~\$7.6B	40% - 60%	4% - 6%	8% - 10%	
Medicare	7%	~\$1.2B	40% - 60%	4% - 6%	11% - 13%	
Marketplace	5%	~\$1.5B	0% - 20%	0% - 3%	5% - 8%	
Weighted Total	~4%	~\$10.3B	~\$5B	4% - 6%	8% - 10%	

Total Company Long-Term Outlook

Strong revenue and earnings growth off of 2022 outlook, enhanced by operating leverage and share repurchases

Premium Revenue Growth	13% - 15%
Hedge to Margins / Operating Leverage	0% - 1%
Net Income Growth	13% - 16%
Share Repurchases	~2%
EPS Growth	15% - 18%





Executive Q&A

Reconciliation of Non-GAAP Financial Measures

Adjustments represent additions and deductions to GAAP net income as indicated in the table below, which include the non-cash impact of amortization of acquired intangible assets, acquisition-related expenses, and the impact of certain expenses and other items that management believes are not indicative of longer-term business trends and operations. Management's opinions on business trends and operations can change, so the adjustments included in the table may not be consistent from period to period.

	2017		2018		2019		2021 Guidance	
Net income per diluted share Adjustments:	\$	(9.07)	\$	10.61	\$	11.47	\$	11.65
Adjustments. Acquisition-related expenses		-		-		-		1.13
Amortization of intangible assets		0.55		0.32		0.27		0.81
Loss (gain) on debt repayment		-		0.33		(0.24)		-
Other (1)		-		0.91		0.10		0.16
Subtotal, adjustments		0.55		1.56		0.13		2.10
Income tax effect		(0.20)		(0.43)		(0.03)		(0.50)
Adjustments, net of tax		0.35		1.13		0.10		1.60
Adjusted net income per diluted share	\$	(8.72)	\$	11.74	\$	11.57	\$	13.25

(1): 2018 includes restructuring costs and loss on sales of subsidiaries, net of gain. 2019 includes restructuring costs. 2021 Guidance includes change in premium deficiency reserves, loss on sale of property, and restructuring costs.

